Oculis (NASDAQ:OCS) Receives Buy Rating from Chardan Capital

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reiterated by research analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $28.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 55.38% from the company’s previous close.

Several other research firms have also commented on OCS. HC Wainwright decreased their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Robert W. Baird increased their price target on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th.

Oculis Trading Up 0.5 %

NASDAQ:OCS opened at $18.02 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. Oculis has a one year low of $10.79 and a one year high of $23.08. The business’s 50-day simple moving average is $18.94 and its 200 day simple moving average is $17.90. The stock has a market cap of $786.79 million, a price-to-earnings ratio of -9.34 and a beta of 0.19.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, sell-side analysts predict that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OCS. Geode Capital Management LLC raised its holdings in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after acquiring an additional 1,800 shares in the last quarter. Bellevue Group AG bought a new position in Oculis in the fourth quarter worth $170,000. Bank of America Corp DE boosted its stake in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Oculis in the 4th quarter valued at $225,000. Finally, Citadel Advisors LLC bought a new position in shares of Oculis during the 4th quarter worth about $389,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.